Investigation of therapeutic potential of cerium oxide nanoparticles in Alzheimer's disease using transgenic .

In the current study, the therapeutic potential of cerium oxide nanoparticles (nCeO) was investigated in a human tau (htau) model of Alzheimer's disease (AD), using as an in vivo model. nCeO synthesised via the hydroxide-mediated approach were characterised using Fourier transform infrared (FTIR), transmission electron microscopy (TEM), X-ray diffraction (XRD) analyses and Raman spectroscopy. Characterisation studies confirmed the formation of pure cubic-structured nCeO and showed that the particles were spherically shaped, with an average size between 20 and 25 nm. The synthesised nCeO were then administered as part of the diet to transgenic for one month, at 0.1 and 1 mM concentrations, and its effect on the biochemical levels of superoxide dismutase (SOD), acetylcholinesterase (AChE), and the climbing activity of flies were studied in a pan-neuronal model (elav; htau) of AD. Using an eye-specific model of htau expression (GMR; htau), the effect of nCeO on htau and autophagy-related (ATG) gene expression was also studied. Dietary administration of nCeO at a concentration of 1 mM restored the activity of SOD similar to that of control, but both concentrations of nCeO failed to modulate the level of AChE, and did not elicit any significant improvements in the climbing activity of elav; htau flies. Moreover, nCeO at a concentration of 1 mM significantly affected the climbing activity of elav; htau flies. nCeO also elicited a significant decrease in htau gene expression at both concentrations and increased the mRNA expression of key autophagy genes ATG1 and ATG18. The results therefore indicate that nCeO aids in replenishing the levels of SOD and tau clearance via the activation of autophagy.